Authorized purpose: syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.
Clinical role
Real-time image viewing, manipulation, 3D visualization, communication, storage, and interventional image fusion or navigation support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Anatomy represented in supported medical images and interventional procedures
Key limitation
Keep in mind: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Anatomy represented in supported medical images and interventional procedures Input: Medical images and data received from supported imaging systems, exchange media, and DICOM network connections.
Who uses it?Intended users: Physicians and trained healthcare professionals responsible for diagnostic or interventional image review.
What does the software produce?Output: Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.
What is its most important limitation?Key limitation: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
Clinical takeaway. Clinical role: syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports verification and validation testing; for the added feature syngo TrueFusion, validation used 28 phantom test data sets, with multiple measurements from different C-arm directions by a board certified cardiologist. Acceptance: mean deviation shall not exceed 3mm with a standard deviation not exceeding 2mm. Reported mean (standard deviation) at C-arm positions A, B, C: experiment 1, 2,92mm (1,29mm), 2,59mm (1,50mm), 2,31mm (1,62mm); experiment 2, 2,76mm (1,31mm), 2,57mm (1,69mm), 2,13mm (1,48mm). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
syngo Application Software provides real-time viewing, image manipulation, 3D visualization, communication, and storage of medical images and data on exchange media for diagnostic viewing, post-processing, and viewing or post-processing during interventional procedures. It may run on a stand-alone workstation, send and receive DICOM data over a network, be deployed on Siemens angiography systems, and be combined with fluoroscopy or radiographic systems for image-guided surgery and interventional cardiology, electrophysiology, oncology, radiology, and neuroradiology.
Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
The exact FDA document reports verification and validation testing; for the added feature syngo TrueFusion, validation used 28 phantom test data sets, with multiple measurements from different C-arm directions by a board certified cardiologist. Acceptance: mean deviation shall not exceed 3mm with a standard deviation not exceeding 2mm. Reported mean (standard deviation) at C-arm positions A, B, C: experiment 1, 2,92mm (1,29mm), 2,59mm (1,50mm), 2,31mm (1,62mm); experiment 2, 2,76mm (1,31mm), 2,57mm (1,69mm), 2,13mm (1,48mm). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The modifications described in this Premarket Notification were supported with verification and validation testing." … "Subject Device Modification: Added software feature “syngo TrueFusion” 2. Objective or Purpose of Test: Validate syngo TrueFusion results 3. Explanation of sample size and Statistical Methods: 28 phantom test data sets". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports verification and validation testing; for the added feature syngo TrueFusion, validation used 28 phantom test data sets, with multiple measurements from different C-arm directions by a board certified cardiologist. Acceptance: mean deviation shall not exceed 3mm with a standard deviation not exceeding 2mm. Reported mean (standard deviation) at C-arm positions A, B, C: experiment 1, 2,92mm (1,29mm), 2,59mm (1,50mm), 2,31mm (1,62mm); experiment 2, 2,76mm (1,31mm), 2,57mm (1,69mm), 2,13mm (1,48mm). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The modifications described in this Premarket Notification were supported with verification and validation testing." … "Subject Device Modification: Added software feature “syngo TrueFusion” 2. Objective or Purpose of Test: Validate syngo TrueFusion results 3. Explanation of sample size and Statistical Methods: 28 phantom test data sets". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K170747 FDA evidence package for syngo Application Software
DesignFDA 510(k) software validation, clinical-image review, and non-clinical substantial-equivalence evidence for the syngo Application Software configuration.
PopulationAnatomy represented in supported medical images and interventional procedures
Scopeexact submission
Tested versionsyngo Application Software (VD20) configuration described in K170747
IndependenceSponsor or vendor study
K170747
The broad multimodality and interventional scope is configuration-dependent; the FDA package does not establish every OEM option or procedure at every site.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K170747 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Medical images and data received from supported imaging systems, exchange media, and DICOM network connections.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package explicitly describes DICOM network send and receive, stand-alone diagnostic or reporting workstations, Siemens angiography systems, and combination with fluoroscopy or radiographic systems.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes stand-alone diagnostic review, post-processing, and reporting workstations; network configuration; Siemens angiography-system deployment; and combinations with fluoroscopy or radiographic systems. Current hosting, service, security, availability, and site configuration remain unverified.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Displayed, manipulated, post-processed, fused, communicated, and stored medical images and procedure-support information.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes stand-alone diagnostic review, post-processing, and reporting workstations; network configuration; Siemens angiography-system deployment; and combinations with fluoroscopy or radiographic systems. Current hosting, service, security, availability, and site configuration remain unverified.
Exact FDA submission
Checked 2026-09-04
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
The FDA package explicitly describes DICOM network send and receive, stand-alone diagnostic or reporting workstations, Siemens angiography systems, and combination with fluoroscopy or radiographic systems.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only physicians and trained healthcare professionals responsible for diagnostic or interventional image review should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K170747 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.
The FDA package describes stand-alone diagnostic review, post-processing, and reporting workstations; network configuration; Siemens angiography-system deployment; and combinations with fluoroscopy or radiographic systems. Current hosting, service, security, availability, and site configuration remain unverified.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package explicitly describes DICOM network send and receive, stand-alone diagnostic or reporting workstations, Siemens angiography systems, and combination with fluoroscopy or radiographic systems.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K170747 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Configured modalities, OEM options, procedures, hardware, and local workflow determine the available functions; the software does not replace qualified professional interpretation or procedural control.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. multimodality medical-image viewing and interventional post-processing software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
One trial record was screened. It evaluates syngo DynaCT Sine Spin with an ARTIS icono system but does not identify the syngo Application Software VD20 configuration in K170747; the record is quarantined. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: HistoSonics Planning Tool is a stand-alone visualization and comparison tool for CT and MR studies used to plan histotripsy target localization, treatment volume, acoustic path, and patient position.
Modality
Radiological images; modality varies or is not specified in FDA list
Beijing Infervision Healthcare Medical Technology Co., Ltd.
Authorized purpose: InferCare RECIST is a post-processing application for longitudinal medical-image display, lesion measurement, registration, tracking, segmentation, three-dimensional reconstruction, and RECIST reporting by trained professionals.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Tumors and lesions in adult patients age 21 and older
Authorized purpose: MI View&GO is a medical diagnostic application for viewing, manipulating, quantifying, analyzing, and comparing PET, nuclear-medicine, CT, and MR images across one or more time points, including labeled oncology, cardiology, neurology, organ-function, and radiotherapy-planning workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Whole body, organs, tumors, heart, brain, and oncology regions
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.